Deep Science, Real Impact
Born out of IIT (BHU) research labs, OxaStore Biotech is reimagining blood diagnostics from first principles making every test more accurate, every sample more stable, and every diagnosis more trustworthy.
Built Where Science Meets Real-World Impact
OxaStore Biotech Pvt. Ltd. is a deep-tech biomedical startup incubated at the Technology Innovation Hub, IIT (BHU) Varanasi. We identified a critical, overlooked flaw in diagnostic medicine: the anticoagulants used to preserve blood were silently corrupting millions of test results and nobody was solving it.
We built a solution from scratch. Our patented oxalate nanoparticle formulation preserves blood integrity for up to 48 hours 6× longer than EDTA while reducing the cost per tube by 80%. One tube. All assays. No workflow change.
With peer-reviewed science, two filed patents, and pathlab validation behind us, we are scaling toward manufacturing, clinical partnerships, and global regulatory approvals. Better diagnostics start with better collection.
Our Vision
To become the main player in the blood collection vial market, collaborating with diagnostic pathlabs and hospitals by enabling more accurate, stable, and affordable diagnostics for every patient.
Our Mission
To transform the foundation of medical diagnostics by redefining how blood is collected, preserved, and analyzed using science to deliver more accurate, reliable, and affordable diagnostic results for every patient.
Research-Backed. Recognition-Earned.
From IIT (BHU) labs to peer-reviewed journals to filed patents every milestone reflects a commitment to science that stands up to scrutiny.
IIT (BHU) Incubation & Seed Funding
Incubated at IIT (BHU) Varanasi one of India’s premier deep-tech institutions. Received $30,000 seed funding to advance from lab to prototype at speed.
Peer-Reviewed in ACS Applied Materials
Our core science is published in ACS Applied Materials & Interfaces (2025) a globally recognized journal validating our oxalate nanoparticle technology.
Dual Indian Patents Secured
Two patent applications filed covering our proprietary nanoparticle formulation (June 2024) and our novel collection vial design (February 2025).
TRL 5–6: Lab to Pathlab Validated
Performance verified with real human blood samples in active pathlab settings. Currently scaling toward clinical validation, manufacturing, and regulatory approvals.
Pathologist-Guided Clinical Design
Every product decision is informed by Dr. Ankur Singh, Director of Ankuram Labs ensuring our technology meets real-world diagnostic requirements.
National & Global Recognition
Featured in startup showcases and biomedical innovation forums. Advancing toward CE marking and CDSCO approvals as part of our global scale-up roadmap.
The Team Behind OxaStore
A multidisciplinary team of scientists and operators united by the mission to improve diagnostic accuracy worldwide.
Dr. Sudip Mukherjee
Co-Founder, Director & Advisor
Assistant Professor of Biomedical Engineering at IIT (BHU), Varanasi. 16 years of research experience in biomaterials, nanotechnology, and medical devices. Collaborator with WL Gore and Establishment Labs.
Devyani Yenurkar
Co-Founder & Chief Scientific Officer
Prime Minister's Research Fellow at Biomedical Engineering, IIT (BHU). Prior experience in pharmaceutical R&D at Medley Pvt. Ltd. Research focused on nanotechnology for unmet clinical problems.
Dr. Ankur Singh
Advisor & Pathlab Expert
Consultant Pathologist and Director of Ankuram Labs, Varanasi (founded 2022). Provides quality and reliable diagnostic services, guiding OxaStore's clinical validation pathway.
Monideepa Shah
Market Research & Fund Acquiring
Senior Manager Research and Communication. Over a decade of cross-functional experience across public health, bioscience research, and lab quality systems at Thermo Fisher Scientific, Biocon Ltd., and Apollo Diagnostics.
What Drives Us Every Day
Scientific Integrity
Every claim we make is backed by validated data. We publish openly, patent responsibly, and hold ourselves to the highest standards of research ethics.
Impact-First Thinking
We measure success not just in revenue, but in diagnostic errors prevented, samples preserved, and lives improved through better clinical data.
Accessible Innovation
Breakthrough technology means nothing if it remains unaffordable. We engineer for cost-efficiency without compromising performance or safety.